Bristol Myers Squibb pens $475M Dragonfly pact for IL-12 program

Bristol Myers Squibb pens $475M Dragonfly pact for IL-12 program

Source: 
Fierce Biotech
snippet: 

Bristol Myers Squibb (BMS) is paying nearly half a billion in near-term and upfronts to licence Dragonfly Therapeutics’ interleukin-12 (IL-12) immunotherapy program.

This program is the early-stage experimental med DF6002, a monovalent IL-12 immunoglobulin Fc fusion protein, which works by creating an inflammatory tumor microenvironment to boost anti-tumor responses.